Bortezomib: Proteasome inhibition as a novel mechanism of cancer therapy-implications for hematological malignancies

Joseph R Mikhael, Hong Chang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.

Original languageEnglish (US)
Pages (from-to)82-86
Number of pages5
JournalLetters in Drug Design and Discovery
Volume4
Issue number2
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Hematologic Neoplasms
Proteasome Endopeptidase Complex
Neoplasms
Proteasome Inhibitors
Therapeutics
Ubiquitin
Multiple Myeloma
Bortezomib
Pharmaceutical Preparations
Proteins

Keywords

  • Bortezomib
  • Cancer
  • Clinical trial
  • Multiple myeloma
  • Proteasome inhibitor

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Molecular Medicine

Cite this

Bortezomib : Proteasome inhibition as a novel mechanism of cancer therapy-implications for hematological malignancies. / Mikhael, Joseph R; Chang, Hong.

In: Letters in Drug Design and Discovery, Vol. 4, No. 2, 03.2007, p. 82-86.

Research output: Contribution to journalArticle

@article{da3a18faf2dc4953a30bc828c128e23f,
title = "Bortezomib: Proteasome inhibition as a novel mechanism of cancer therapy-implications for hematological malignancies",
abstract = "The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.",
keywords = "Bortezomib, Cancer, Clinical trial, Multiple myeloma, Proteasome inhibitor",
author = "Mikhael, {Joseph R} and Hong Chang",
year = "2007",
month = "3",
doi = "10.2174/157018007779422541",
language = "English (US)",
volume = "4",
pages = "82--86",
journal = "Letters in Drug Design and Discovery",
issn = "1570-1808",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Bortezomib

T2 - Proteasome inhibition as a novel mechanism of cancer therapy-implications for hematological malignancies

AU - Mikhael, Joseph R

AU - Chang, Hong

PY - 2007/3

Y1 - 2007/3

N2 - The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.

AB - The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.

KW - Bortezomib

KW - Cancer

KW - Clinical trial

KW - Multiple myeloma

KW - Proteasome inhibitor

UR - http://www.scopus.com/inward/record.url?scp=33846299169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846299169&partnerID=8YFLogxK

U2 - 10.2174/157018007779422541

DO - 10.2174/157018007779422541

M3 - Article

AN - SCOPUS:33846299169

VL - 4

SP - 82

EP - 86

JO - Letters in Drug Design and Discovery

JF - Letters in Drug Design and Discovery

SN - 1570-1808

IS - 2

ER -